AAPL VS SPRO Stock Comparison

Performance

AAPL
100/100

AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.

SPRO
10/100

SPRO returned -39.36% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AAPL
78/100

38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.

SPRO
81/100

4 analysts offer 12-month price targets for SPRO. Together, they have an average target of 0, the most optimistic target put SPRO at 0 within 12-months and the most pessimistic has SPRO at 0.

Sentiment

AAPL
70/100

AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.

SPRO

"Sentiment" not found for SPRO

Technicals

AAPL
18/100

AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

SPRO
50/100

SPRO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

AAPL
100/100

AAPL has missed earnings 1 times in the last 20 quarters.

SPRO
21/100

SPRO has missed earnings 6 times in the last 20 quarters.

Profit

AAPL
76/100

Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.

SPRO
13/100

Out of the last 20 quarters, SPRO has had 1 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

AAPL
45/100

AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

SPRO
49/100

SPRO has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

Dividend

AAPL
50/100

AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.

SPRO

"Dividend" not found for SPRO

All score calculations are broken down here to help you make more informed investing decisions

Apple Inc. Summary

Nasdaq / AAPL

Technology

Consumer Electronics

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.

Spero Therapeutics, Inc. Common Stock Summary

Nasdaq / SPRO

Healthcare

Biotechnology

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio